Pentaglobin

Phase 2Small molecule

MMedical University of Vienna

Pentaglobin is one of 49 small molecule programs targeting Septic Shock. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

COVID-19Active, not recruiting

Septic ShockPhase 2

Active, not recruiting

COVID-19Phase 2/Phase 3

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Stivarga

Bayer

Preclinical

1 2

Singulair

AstraZeneca

Preclinical

1 3

Pentaglobin

MMedical University of Vienna

Phase 2

1 4

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 5

Benadryl

PParkedale

Preclinical

1 6

Nitrostat

VViatris Specialty LLC

Preclinical

1 7

Aquasol E

NNational Eye Institute (NEI)

Preclinical

1 8

Achromycin V

WWyeth-Lederle Vaccines

Preclinical

—9

Piperacillin/tazobactam

Pfizer

Preclinical

1 10

Orap

Teva

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Septic Shock1 trial

Effects on Microcirculation of IgGAM in Severe Septic/Septic Shock Patients.

Completed·UUniversità Politecnica delle Marche·Phase 2·NCT02655133·20 enrolled

Infections1 trial

Pentaglobin in CRE and PA Neutropenic Infections

Active, not recruiting·GGruppo Italiano Trapianto di Midollo Osseo·Phase 2·NCT03494959·120 enrolled

COVID-191 trial

Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)

Unknown status·MMedical University of Vienna·Phase 2/3·NCT04351724·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Pentaglobin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pentaglobin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pentaglobin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Vienna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMedical University of Vienna

Pentaglobin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Septic Shock1 trial

Infections1 trial

COVID-191 trial

References

Drug Info

Quick Facts

Related News